• Ascletis Pharma reported positive Phase II results for oral diabetes treatment ASC30, which met its primary endpoint and all secondary endpoints.
• The once-daily tablet significantly reduced blood sugar levels versus placebo, while also delivering weight loss in participants with type 2 diabetes.
• No participants discontinued treatment because of gastrointestinal adverse events; no liver safety signals or drug-related serious adverse events were observed.
• A separate global Phase III program for obesity is enrolling approximately 4,600 participants across two pivotal trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN83118) on October 28, 2026, and is solely responsible for the information contained therein.